KRASG12D抑制剂管线持续扩展
The KRASG12D Inhibitor Pipeline Grows.
PubMed 文献 · Cancer Discov · 2026-01-01
At this year's ASCO Annual Meeting, investigators also presented encouraging early clinical data for several KRASG12D-selective inhibitors, including RNK08594, GFH375, and DN022150, suggesting that this type of drug could play a role in the treatment of several solid tumors, such…
要点
- RNK08594、GFH375和DN022150在ASCO年会报告早期临床数据。
- KRASG12D抑制剂可能用于胰腺导管腺癌和非小细胞肺癌等实体瘤。
- 早期数据令人鼓舞,支持进一步临床开发。
核心结论
- KRASG12D选择性抑制剂的早期临床数据令人鼓舞,提示其可能在多种实体瘤治疗中发挥作用。
研究设计与样本
- 本文为ASCO年会早期临床数据报道,涉及RNK08594、GFH375和DN022150等KRASG12D选择性抑制剂。
主要发现
- RNK08594、GFH375和DN022150的早期临床数据令人鼓舞。
- 上述药物提示可能用于胰腺导管腺癌和非小细胞肺癌等实体瘤的治疗。
临床怎么用
- 关注KRASG12D选择性抑制剂在胰腺导管腺癌和非小细胞肺癌等实体瘤中的临床开发进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At this year's ASCO Annual Meeting, investigators also presented encouraging early clinical data for several KRASG12D-selective inhibitors, including RNK08594, GFH375, and DN022150, suggesting that this type of drug could play a role in the treatment of several solid tumors, such as pancreatic ductal adenocarcinoma and non-small cell lung cancer.
来源:Cancer Discov,查看原文。版权归原作者所有。
引用
- The KRASG12D Inhibitor Pipeline Grows. Cancer Discov. 2026. PMID: 42299111. doi:10.1158/2159-8290.CD-NW2026-0069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。